SciSparc says US publishes patent application for MDMA-PEA combo targeting PTSD
SPRC•SPRC•SPRC•SPRC•The disclosure follows the FDA’s July 14, 2026 final guidance on clinical investigations for psychedelic drugs, which explicitly covers MDMA.
The NeuroThera-Clearmind collaboration now totals 13 published patent applications worldwide, building an intellectual-property position in psychedelic-derived CNS programs.
SciSparc said the U.S. published a patent application on combining MDMA with N-acylethanolamines such as PEA for PTSD treatment.
The application also targets anxiety and eating disorders, and focuses on dosing, side effects, potency and the therapeutic window for the MDMA-PEA approach.
